SRC and acute myeloid leukemia: These findings nominate <i>ACSL4</i>-driven ferroptosis susceptibility as a lineage-specific vulnerability rendering monocytic AML selectively sensitive to SRC-directed therapy while resistant to BCL2 inhibition.